



**Contact Information:**  
**Jon J. Snyder, President and CEO**  
**Neuros Medical, Inc.**  
**(440) 951-BLOK (2565)**  
**(440) 487-7515**  
[jsnyder@neurosmedical.com](mailto:jsnyder@neurosmedical.com)

**For Immediate Release:**

## **Neuros Medical Receives Regulatory Approval to Commence Pilot Study**

**Cleveland, OH, November 28, 2011** – Neuros Medical, Inc., a medical device company announced it has received an Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration allowing it to commence a pilot clinical trial to evaluate the Company’s patented high frequency Electrical Nerve Block™ technology for use in acute treatment of pain in the residual limb of amputees.

The IDE approval builds off of the Company’s successful first-in-man feasibility study earlier this year, in which four out of five patients reported significant pain reduction, at times reducing pain scores to zero. The feasibility study was the first human test of the Company’s high frequency Electrical Nerve Block technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S.

Jon J. Snyder, President and CEO of Neuros Medical, said, “We are very pleased with the IDE approval and look forward to commencing the pilot study to provide longer term safety and efficacy data of our Electrical Nerve Block technology in a larger set of patients.”

\* \* \*

### **About Neuros Medical, Inc.**

Neuros Medical, a Cleveland, Ohio based neuromodulation company, is focused on developing proprietary therapies for unmet needs to patients worldwide. The Company’s patented platform technology, Electrical Nerve Block™, is focused on the elimination of chronic pain in a variety of applications including amputation pain, chronic post-surgical pain, chronic migraine, and trigeminal neuralgia.